Drug intelligence / Profile preview

OBT597

Development stage: Preclinical
Lead developer: Oxford BioTherapeutics
Administration: Intravenous

Overview

OBT597 is an early-stage oncology drug candidate currently in the discovery phase, developed by Oxford BioTherapeutics. As of the latest pipeline disclosures, the specific biological target, therapeutic modality, and primary disease indications remain undisclosed. The program is part of Oxford BioTherapeutics' broader portfolio focused on developing novel cancer therapies, often utilizing their proprietary OGAP (Oxford Genome Anatomy Project) platform to identify unique tumor-associated antigens for the development of antibody-drug conjugates (ADCs) or T-cell engagers (TCEs).

Targets

LY75 (Dendritic cell receptor DEC–205)

Beyond the preview

Go deeper on OBT597.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OBT597.

Explore the full profile